Last Updated: November 16, 2026

Details for Patent: 11,786,531

« Back to Dashboard


Which drugs does patent 11,786,531 protect, and when does it expire?

Patent 11,786,531 protects BRUKINSA and is included in two NDAs.

This patent has one patent family member in one country.

Summary for Patent: 11,786,531
Title:Methods of treating B-cell proliferative disorder
Abstract:Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.
Inventor(s):Jason Paik, Tommi Salmi, Ying Ou
Assignee: BeOne Medicines I GmbH
Application Number:US18/098,938
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,786,531
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

United States Patent 11,786,531: Zanubrutinib CYP3A-Inducer Claims, Scope and Patent Landscape

U.S. Patent No. 11,786,531 protects specific methods of using zanubrutinib, marketed as Brukinsa, when a patient with a listed B-cell malignancy must receive a moderate CYP3A inducer. The core protected regimen is zanubrutinib at approximately 640 mg per day, generally 320 mg twice daily, administered concomitantly with the inducer.

The patent is a narrow clinical-use patent rather than a composition-of-matter patent. Its commercial value depends on whether the product label, prescribing practice, or a generic or competing BTK inhibitor product directs or encourages the claimed dose adjustment. The claims cover CLL, SLL, WM, MCL, MZL and FL, and expressly identify seven moderate CYP3A inducers: rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital and nafcillin.

What does U.S. Patent 11,786,531 protect?

The patent has three independent method claims:

Independent claim Required patient-selection step Required treatment Covered diseases
Claim 1 Patient is receiving a moderate CYP3A inducer Concomitant zanubrutinib at about 640 mg total daily dose CLL, SLL, WM, MCL, MZL or FL
Claim 11 Determine whether patient is receiving a moderate CYP3A inducer; treat if present Concomitant zanubrutinib at about 640 mg total daily dose CLL, SLL, WM, MCL, MZL or FL
Claim 21 Assess whether the inducer can be avoided; if not, treat concomitantly Concomitant zanubrutinib at about 640 mg total daily dose CLL, SLL, WM, MCL, MZL or FL

The practical center of gravity is the combination of four elements:

  1. A patient has one of the claimed B-cell malignancies.
  2. The patient is taking, or cannot avoid taking, a moderate CYP3A inducer.
  3. Zanubrutinib is administered at about 640 mg per day.
  4. The two therapies are administered concomitantly.

The patent does not claim zanubrutinib generally, the 160 mg twice-daily regimen generally, or every drug interaction involving zanubrutinib. It targets a dose-adjustment protocol for a defined pharmacokinetic problem.

How do the dependent claims narrow the patent?

Claims 2 and 12 and 22 specify administration at approximately 320 mg twice daily. The twice-daily formulation is commercially important because it is the most direct clinical implementation of the claimed total daily dose.

Disease-specific dependent claims identify:

  • CLL: claims 3, 13 and 23
  • SLL: claims 4, 14 and 24
  • WM: claims 5, 15 and 25
  • MCL: claims 6, 16 and 26
  • MZL: claims 7, 17 and 27

The independent claims also include FL, but the supplied dependent claims do not separately recite FL. That distinction matters in claim construction and infringement analysis. A product or clinical protocol directed to FL can still fall within claims 1, 11 or 21 if all other limitations are met.

Claims 8, 18 and 28 identify the moderate CYP3A inducers:

Listed inducer Potential claim relevance
Rifabutin Directly recited
Bosentan Directly recited
Efavirenz Directly recited
Etravirine Directly recited
Modafinil Directly recited
Phenobarbital Directly recited
Nafcillin Directly recited

A claim does not necessarily require one of these seven drugs unless the accused conduct is evaluated under the corresponding dependent claim. The independent claims use the broader category of a “moderate CYP3A inducer.”

What clinical comparison does Patent 11,786,531 include?

Claims 9, 19 and 29 add a comparative clinical outcome. They require that the zanubrutinib regimen:

  • Prolong PFS compared with a comparable patient receiving ibrutinib at 420 mg once daily; or
  • Produce a lower rate of atrial fibrillation or atrial flutter than that comparator.

These are narrower claims than the core dosing claims. The comparison introduces additional factual and evidentiary questions, including how “comparable patient” is defined, whether the comparison is based on a clinical trial or other evidence, and whether the claimed result is a required limitation or an intended result under the applicable claim-construction analysis.

The comparative claims are commercially relevant because ibrutinib is the principal first-generation covalent BTK inhibitor comparator in the patent and in the clinical literature. Zanubrutinib’s development program emphasized BTK selectivity and cardiovascular tolerability relative to ibrutinib. FDA labeling for Brukinsa identifies atrial fibrillation and flutter among clinically relevant adverse reactions, while clinical studies have reported differences in cardiovascular event rates across BTK inhibitors. Those results do not automatically establish infringement of claims 9, 10, 19, 20, 29 or 30. The specific comparator population and evidence must satisfy the claim language.[1][2]

Why is the CYP3A-inducer dosing issue commercially important?

Zanubrutinib is metabolized primarily through CYP3A. CYP3A inducers can reduce systemic exposure and potentially reduce therapeutic activity. The FDA-approved Brukinsa prescribing information addresses concomitant use with CYP3A inhibitors and inducers and provides dose-management instructions for situations in which an interacting medicine cannot be avoided.[1]

The patent’s 640 mg daily regimen is therefore directed to a clinically defined exception to the standard regimen. Brukinsa has generally been administered at:

  • 160 mg twice daily; or
  • 320 mg once daily,

depending on the formulation and labeling applicable to the indication and date. The patent focuses on an increased total daily dose of approximately 640 mg, generally 320 mg twice daily, when a moderate inducer is present.

This creates a potential intersection between patent scope and FDA labeling. If the approved label instructs physicians to increase zanubrutinib to 320 mg twice daily in the presence of a moderate CYP3A inducer, the label may provide evidence of induced infringement or contributory infringement theories against a manufacturer, subject to the product’s exact label and the requirements of 35 U.S.C. § 271.[3]

What is the Orange Book status of Patent 11,786,531?

The Orange Book is the FDA’s listing of patents and exclusivity for approved drug products. Patent 11,786,531 should be evaluated against the Orange Book entries for Brukinsa, including the listed active ingredient, dosage-form, formulation and method-of-use patents.[4]

A method-of-use patent can be listed in the Orange Book if it claims an approved method of using the drug. Its listing can require an abbreviated new drug application applicant to make a patent certification, including a Paragraph IV certification if the applicant asserts that the patent is invalid, unenforceable or will not be infringed.[5]

The supplied claim set is directed to a method of use, not to:

  • Zanubrutinib’s chemical structure;
  • A crystalline form;
  • A tablet composition;
  • A capsule composition;
  • A general BTK-inhibition method;
  • A manufacturing process; or
  • A broad treatment method without the CYP3A-inducer limitation.

The commercial significance of an Orange Book listing depends on whether the patent is listed for the relevant Brukinsa strength and dosage form and whether its use code corresponds to the approved CYP3A-inducer dosing instruction. A Paragraph IV notice can trigger patent litigation and, if statutory conditions are met, a 30-month stay of FDA approval under the Hatch-Waxman framework.[5]

When does Patent 11,786,531 lose exclusivity?

The patent’s expiration date cannot be determined from the claims alone. The legally operative term depends on the patent’s earliest effective nonprovisional or international filing date, terminal disclaimers, patent-term adjustment, patent-term extension and any applicable patent-term calculations under 35 U.S.C. §§ 154 and 156.[3]

The relevant term analysis is:

Term issue Relevance
Earliest effective filing date Establishes the base 20-year patent term
Patent-term adjustment Can extend the term for qualifying USPTO delay
Terminal disclaimer Can limit the patent to the expiration of another patent
Patent-term extension May apply only in statutory circumstances tied to regulatory review
Patent-term restoration or pediatric exclusivity May affect effective market protection
Post-grant proceedings or litigation Can cancel, amend or limit claims before nominal expiration

The patent’s issue date, December 2023, does not itself determine the expiration date. A reliable freedom-to-operate conclusion requires the patent’s continuity data, terminal-disclaimer record and USPTO term calculation.[6]

How strong is the patent estate for the CYP3A-inducer regimen?

The patent is strongest against conduct that closely follows the literal claim language:

  • One of the six named diseases, or FL under an independent claim;
  • A recognized moderate CYP3A inducer;
  • Concomitant administration;
  • Approximately 640 mg total daily zanubrutinib;
  • A clinical or prescribing protocol that expressly directs the regimen.

The estate is weaker where the conduct differs materially from the claims:

  • Zanubrutinib is administered at 320 mg once daily rather than 320 mg twice daily;
  • The interacting drug is classified as a strong or weak rather than moderate CYP3A inducer;
  • The dose is adjusted by a different amount;
  • The patient has a disease outside the claimed list;
  • The inducer is discontinued before zanubrutinib administration;
  • The treatment is not concomitant;
  • The accused product label does not encourage the patented method.

The use of “about” introduces a scope question around dose variance. A court would typically assess the intrinsic evidence, specification, prosecution history and accepted clinical dosing conventions. A materially different daily dose may avoid literal infringement, but the doctrine of equivalents could become relevant depending on prosecution history and the reason for the claimed numerical range.

What Paragraph IV challenges could target the patent?

A generic applicant seeking approval for zanubrutinib may challenge the patent through a Paragraph IV certification if the patent is listed against the reference product and the applicant’s proposed labeling would cover the patented use.

Potential invalidity theories could include:

Theory Potential issue
Anticipation Whether one prior-art reference discloses the full inducer, disease, concomitant-use and 640 mg regimen
Obviousness Whether dose escalation in the presence of CYP3A induction would have been predictable with a reasonable expectation of success
Written description Whether the patent adequately supports all listed diseases, inducers and dose combinations
Enablement Whether the specification enables the full breadth without undue experimentation
Indefiniteness Meaning of “about,” “moderate CYP3A inducer,” “comparable patient” and “prolongs”
Double patenting Whether the claims improperly overlap with an earlier related patent
Inequitable conduct Whether material information was withheld or misrepresented during prosecution

The patent holder could respond that the claimed regimen is not a routine dose adjustment because CYP3A induction can materially reduce exposure, and that the specification and clinical pharmacology data support a specific compensating dose. The comparative PFS and atrial-fibrillation claims may face separate enablement, written-description and proof issues because they require an outcome relative to an ibrutinib comparator.

What patent litigation affects Brukinsa and zanubrutinib?

Zanubrutinib is associated with BeiGene, Ltd. and its U.S. commercial operations. Brukinsa has accumulated patent protection across several categories, including composition, formulations, treatment methods and pharmacokinetic or drug-interaction uses.[1][4]

Patent 11,786,531 should be separated from litigation involving:

  • The zanubrutinib active ingredient;
  • Solid-state or crystalline forms;
  • Tablet or capsule formulations;
  • General use in WM, MCL, MZL, CLL or SLL;
  • BTK-inhibitor combination therapy;
  • Manufacturing or process patents;
  • Other CYP3A-interaction patents.

A litigation search should track the patent’s USPTO prosecution history, the FDA Orange Book listing, district-court complaints, ANDA notices, claim-construction rulings, inter partes review petitions and any terminal-disclaimer relationship. The supplied claims do not establish that the patent has been litigated, challenged in an inter partes review, or settled.

How does this patent compare with competing BTK-inhibitor patent estates?

Product Active ingredient Relevant interaction issue Patent-landscape distinction
Brukinsa Zanubrutinib CYP3A inducers and inhibitors can alter exposure Patent 11,786,531 targets a 640 mg daily inducer regimen
Imbruvica Ibrutinib Extensive CYP3A interaction management 420 mg once-daily ibrutinib is the express comparator in certain claims
Calquence Acalabrutinib CYP3A inhibitors and inducers affect exposure Separate composition, formulation and method-of-use estate
Jaypirca Pirtobrutinib CYP3A and transporter interactions Later-generation BTK inhibitor with separate regulatory and patent protection

The patent does not block use of ibrutinib, acalabrutinib or pirtobrutinib. It can become relevant when a company markets zanubrutinib with labeling or promotional material that recommends the claimed dose in the presence of a moderate inducer.

What generic entry risks exist for Brukinsa?

Generic entry risk has two distinct dimensions.

First, a generic applicant may avoid the patent through a labeling carve-out that excludes the CYP3A-inducer regimen. That approach depends on whether the carved-out labeling remains adequate for FDA approval and whether the generic’s conduct nevertheless induces use of the patented method.

Second, a generic applicant may challenge the patent under Paragraph IV. The likely pressure points are the breadth of the moderate-inducer category, the “about 640 mg” limitation, the clinical significance of dose escalation and the predictability of the regimen from prior pharmacokinetic knowledge.

A launch before patent expiry could expose the applicant to infringement litigation, an injunction risk and damages. A launch after a final invalidity ruling, noninfringement ruling or settlement would present a different risk profile.

What manufacturing and geographic barriers remain?

Patent 11,786,531 does not claim a manufacturing process, raw-material route or solid-state form. It therefore does not independently create a manufacturing barrier to producing zanubrutinib. Manufacturing freedom to operate must be assessed against separate patents covering:

  • The active pharmaceutical ingredient;
  • Intermediates;
  • Crystalline or polymorphic forms;
  • Tablet and capsule compositions;
  • Coatings and excipients;
  • Manufacturing processes;
  • Analytical methods; and
  • Supplier or license agreements.

The patent is a U.S. right. Equivalent applications or granted patents in Europe, China, Japan, Canada, Australia and other markets require separate analysis. U.S. claim scope cannot be imported into foreign jurisdictions without examining the local prosecution record, granted claims, term and regulatory linkage system.

What is the commercial exposure of the patent?

The exposure is concentrated in patients requiring a moderate CYP3A inducer while receiving zanubrutinib for one of the listed B-cell malignancies. The patent does not cover the entire Brukinsa market. Its value is therefore narrower than a composition patent or a broad indication patent.

The exposure rises if:

  • The FDA label expressly recommends 320 mg twice daily with moderate inducers;
  • Moderate-inducer use is common in oncology patients;
  • Generic labeling reproduces the dose-adjustment instruction;
  • The label includes all or most of the claimed diseases;
  • The patent is listed in the Orange Book;
  • The patent term extends beyond composition or formulation protection; and
  • No practical therapeutic substitute avoids the interaction.

It falls if clinicians commonly discontinue or replace the inducer, use an alternative BTK inhibitor, apply a different zanubrutinib dose, or treat a disease outside the claims.

Key Takeaways

  • U.S. Patent 11,786,531 is a method-of-use patent centered on zanubrutinib at approximately 640 mg daily, usually 320 mg twice daily, during treatment with a moderate CYP3A inducer.
  • Claims 1, 11 and 21 establish three versions of the same clinical protocol: concomitant use, screening for inducer use, and assessing whether the inducer can be avoided.
  • The claimed diseases are CLL, SLL, WM, MCL, MZL and FL.
  • The expressly named inducers are rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital and nafcillin.
  • Claims 9, 10, 19, 20, 29 and 30 add comparisons to ibrutinib 420 mg once daily involving PFS or atrial fibrillation/flutter.
  • The patent does not claim zanubrutinib generally, its chemical structure, its formulation or its manufacturing process.
  • Orange Book listing, approved use codes, continuity data, terminal disclaimers and the official patent-term calculation determine the patent’s practical regulatory and exclusivity impact.
  • Generic risk is highest if an ANDA label recommends the patented 320 mg twice-daily regimen and lowest if the use can be lawfully carved out or avoided.
  • The patent’s strength is concentrated but potentially meaningful because the claimed dose adjustment may track FDA-approved prescribing instructions.

FAQs

Does Patent 11,786,531 cover the standard 160 mg twice-daily Brukinsa dose?

No. The supplied claims require approximately 640 mg total daily zanubrutinib, with dependent claims specifying approximately 320 mg twice daily.

Does the patent cover zanubrutinib treatment for follicular lymphoma?

Yes, follicular lymphoma is included in the independent claims. The supplied dependent claims separately identify CLL, SLL, WM, MCL and MZL but do not separately recite FL.

Can a generic avoid the patent by omitting moderate CYP3A-inducer language?

Potentially, if the FDA-approved labeling can be carved out and the generic’s label and conduct do not encourage the patented method. The result depends on the final label and the infringement theory.

Are claims comparing zanubrutinib with ibrutinib automatically infringed whenever zanubrutinib has better outcomes?

No. The claimed comparison requires the specified patient-treatment context, comparator dose and claimed clinical result. Evidence must establish the applicable claim limitations.

Does this patent block manufacture of zanubrutinib outside the United States?

No. The claims provided are U.S. method claims. They do not independently block API manufacture, formulation manufacture or sales outside the United States.

References

  1. U.S. Food and Drug Administration. (2024). Brukinsa (zanubrutinib) prescribing information. BeiGene USA, Inc.

  2. Tam, C. S., Opat, S., D’Sa, S., Jurczak, W., Lee, H.-P., Cull, G., Owen, R. G., Tedeschi, A., Brown, J. R., Marlton, P., et al. (2020). A randomized phase 3 trial of zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia. Blood, 136(18), 2038-2050.

  3. United States Code. (2024). 35 U.S.C. §§ 154, 156 and 271.

  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.

  5. United States Code. (2024). 21 U.S.C. § 355(j).

  6. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension resources.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,786,531

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Beone Medicines Usa BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) RECEIVING A MODERATE CYP3A INDUCER, IN COMBINATION WITH OBINUTUZUMAB, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY ⤷  Start Trial
Beone Medicines Usa BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) RECEIVING A MODERATE CYP3A INDUCER ⤷  Start Trial
Beone Medicines Usa BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ADULT PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM) RECEIVING A MODERATE CYP3A INDUCER ⤷  Start Trial
Beone Medicines Usa BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) RECEIVING A MODERATE CYP3A INDUCER ⤷  Start Trial
Beone Medicines Usa BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) RECEIVING A MODERATE CYP3A INDUCER, WHO HAVE RECEIVED AT LEAST ONE ANTI–CD20-BASED REGIMEN ⤷  Start Trial
Beone Medicines Usa BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) RECEIVING A MODERATE CYP3A INDUCER, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY ⤷  Start Trial
Beone Medicines Usa BRUKINSA zanubrutinib CAPSULE;ORAL 213217-001 Nov 14, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING A MODERATE CYP3A INDUCER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,786,531

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2023240180 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.